A meta-analysis of the placebo rates of remission and response in clinical trials of active crohn’s disease
Open Access
- 1 May 2004
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 126 (5) , 1257-1269
- https://doi.org/10.1053/j.gastro.2004.01.024
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Optimal Crohn's disease activity index (CDAI) response criteria is defined by decreaseȦ100 pointsGastroenterology, 2003
- A randomized, placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF-α, in patients with moderate to severe Crohn's diseaseGastroenterology, 2003
- CDP870, a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD)Gastroenterology, 2003
- Individual patient‐ versus group‐level data meta‐regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly headStatistics in Medicine, 2002
- Is the Placebo Powerless? An Analysis of Clinical Trials Comparing Placebo With no TreatmentObstetrical & Gynecological Survey, 2001
- A Randomized, Double-Blind, Placebo-Controlled Trial of the Oral Mesalamine (5-ASA) Preparation, Asacol, in the Treatment of Symptomatic Crohn??s Colitis and IleocolitisJournal of Clinical Gastroenterology, 1994
- Slow-Release 5-Aminosalicylic Acid Therapy in Children with Small Intestinal Crohnʼs DiseaseJournal of Pediatric Gastroenterology and Nutrition, 1993
- Double blind, placebo controlled trial of metronidazole in Crohn's disease.Gut, 1991
- Final Report on a Placebo-Controlled, Double-Blind, Randomized, Multicentre Trial of Cyclosporin Treatment in Active Chronic Crohn's DiseaseScandinavian Journal of Gastroenterology, 1991
- Sulphadoxine-Pyrimethamine Therapy in Crohn’s DiseaseDigestion, 1982